Two cancers in childhood linked with educational deficits

British researchers, wanting to know if any specific childhood cancers were associated with an educational deficit in adulthood, went looking. They found two.

In this enormous study (Lancashire ER. J Natl Cancer Inst. 2010; doi:10.1093/jnci/djp49), researchers had at their disposal a very rare population-based cohort of over 10,000 cancer survivors, thanks to the British Childhood Cancer Survivor Study.

For a control arm, they used the General Household Survey of Great Britain.

The findings indicate that childhood survivors of Leukemia and Central Nervous System (CNS) tumors reached lower-than-expected educational levels compared with the general population. This was especially true if treatment included head irradiation.

Principal researcher
E.R. Lancashire
The Centre for Childhood Cancer Survivor Studies
School of Health and Population Sciences
The University of Birmingham

Sources: HemOncToday and ScienceDaily.

By Ross Bonander

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap